CA2686874C - Polymorphism in the apo(a) gene predict responsiveness to acetylsalicylic acid treatment - Google Patents

Polymorphism in the apo(a) gene predict responsiveness to acetylsalicylic acid treatment Download PDF

Info

Publication number
CA2686874C
CA2686874C CA2686874A CA2686874A CA2686874C CA 2686874 C CA2686874 C CA 2686874C CA 2686874 A CA2686874 A CA 2686874A CA 2686874 A CA2686874 A CA 2686874A CA 2686874 C CA2686874 C CA 2686874C
Authority
CA
Canada
Prior art keywords
apo
polymorphism
acetylsalicylic acid
acid treatment
predict responsiveness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2686874A
Other languages
English (en)
French (fr)
Other versions
CA2686874A1 (en
Inventor
Paul Ridker
Daniel Chasman
Dov Shiffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Celera Corp
Original Assignee
Brigham and Womens Hospital Inc
Celera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, Celera Corp filed Critical Brigham and Womens Hospital Inc
Publication of CA2686874A1 publication Critical patent/CA2686874A1/en
Application granted granted Critical
Publication of CA2686874C publication Critical patent/CA2686874C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
CA2686874A 2007-05-09 2008-05-09 Polymorphism in the apo(a) gene predict responsiveness to acetylsalicylic acid treatment Active CA2686874C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91685807P 2007-05-09 2007-05-09
US60/916,858 2007-05-09
PCT/US2008/005986 WO2008140776A1 (en) 2007-05-09 2008-05-09 Polymorphism in the apo (a) gene predict responsiveness to acetylsalicylic acid treatment

Publications (2)

Publication Number Publication Date
CA2686874A1 CA2686874A1 (en) 2008-11-20
CA2686874C true CA2686874C (en) 2021-10-19

Family

ID=40002550

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2686874A Active CA2686874C (en) 2007-05-09 2008-05-09 Polymorphism in the apo(a) gene predict responsiveness to acetylsalicylic acid treatment

Country Status (7)

Country Link
US (6) US7943317B2 (enExample)
EP (1) EP2150627B1 (enExample)
JP (2) JP5601685B2 (enExample)
CN (1) CN101743325B (enExample)
BR (1) BRPI0811309B1 (enExample)
CA (1) CA2686874C (enExample)
WO (1) WO2008140776A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2150627B1 (en) * 2007-05-09 2013-09-11 The Brigham and Women's Hospital, Inc. Polymorphism in the apo (a) gene predict responsiveness to acetylsalicylic acid treatment
WO2013080227A1 (en) * 2011-11-28 2013-06-06 Decode Genetics Ehf Genetic variants useful for risk assessment of arterial disease
US20150227678A1 (en) * 2014-02-09 2015-08-13 Lane Bernard SCHEIBER Method to represent the nucleotide elements of a dna sequence as numerical elements to include adenine being assigned the value one, guanine being assigned the value two, cytosine being assigned the value three, and thymine being assigned the value four

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1806867C3 (de) * 1968-11-04 1974-07-18 Byk-Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung substituierter 4-Hydroxy pyrimidine
AU2001274563A1 (en) * 2000-06-22 2002-01-02 Takeda Chemical Industries Ltd. Novel polypeptide and its dna
CA2886504C (en) 2002-12-20 2019-01-08 Celera Corporation Wdr12 polymorphisms associated with myocardial infarction, methods of detection and uses thereof
EP1613774A2 (en) * 2003-03-10 2006-01-11 Applera Corporation Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
JP5649263B2 (ja) * 2003-11-26 2015-01-07 セレラ コーポレーション 心臓血管障害および薬物応答に関連した遺伝子多型、それらの検出方法および用途
US20050287558A1 (en) * 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
WO2005110039A2 (en) 2004-05-07 2005-11-24 Applera Corporation Genetic polymorphisms associated with vascular diseases, methods of detection and uses thereof
US7381536B2 (en) * 2005-03-01 2008-06-03 Gurbel Paul A Assessment of cardiac health and thrombotic risk in a patient
CA2609618C (en) * 2005-05-24 2016-01-05 Flamel Technologies Novel acetylsalicylic acid formulations
US7972802B2 (en) * 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
WO2008132763A2 (en) * 2007-04-30 2008-11-06 Decode Genetics Ehf Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
EP2150627B1 (en) * 2007-05-09 2013-09-11 The Brigham and Women's Hospital, Inc. Polymorphism in the apo (a) gene predict responsiveness to acetylsalicylic acid treatment

Also Published As

Publication number Publication date
US20140024623A1 (en) 2014-01-23
US20170335394A1 (en) 2017-11-23
US20200248262A1 (en) 2020-08-06
US20090004187A1 (en) 2009-01-01
US20110206667A1 (en) 2011-08-25
JP2014036674A (ja) 2014-02-27
CN101743325B (zh) 2014-07-09
EP2150627B1 (en) 2013-09-11
JP2010528262A (ja) 2010-08-19
CA2686874A1 (en) 2008-11-20
BRPI0811309A2 (pt) 2020-09-15
US20150284799A1 (en) 2015-10-08
BRPI0811309B1 (pt) 2022-03-03
WO2008140776A1 (en) 2008-11-20
US7943317B2 (en) 2011-05-17
US11697850B2 (en) 2023-07-11
US10550433B2 (en) 2020-02-04
EP2150627A4 (en) 2011-02-23
EP2150627A1 (en) 2010-02-10
CN101743325A (zh) 2010-06-16
JP5601685B2 (ja) 2014-10-08

Similar Documents

Publication Publication Date Title
EP2310525A4 (en) ASSOCIATED GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, DETECTION METHODS AND THEIR USE
WO2008088861A3 (en) Gene polymorphisms predictive for dual tki therapy
CL2011003129A1 (es) Procedimiento para determinar riesgo de padecer enfermedad cardiovascular que comprende determinar la presencia de polimorfismos de un solo nucleotido (snp)
WO2009092035A3 (en) Methods and compositions for the analysis of biological molecules
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment
WO2008089465A3 (en) Gene polymorphisms as sex-specific predictors in cancer therapy
WO2010001419A3 (en) Copy number variations predictive of risk of schizophrenia
GB2477868A (en) Methods and systems for incorporating multiple environmental and genetic risk factors
WO2008109423A8 (en) Multigene assay to predict outcome in an individual with glioblastoma
WO2007067968A3 (en) Effects of inhibitors of fgfr3 on gene transcription
WO2006023719A3 (en) Identification of snp’s associated with schizophrenia, schizoaffective disorder and bipolar disorder
EP2071025A4 (en) PRIMER SET FOR THE REINFORCEMENT OF THE UGT1A1 GENE, REAGENT FOR THE REINFORCEMENT OF THE UGT1A1 GENE THEREFOR AND APPLICATION THEREOF
WO2008088893A3 (en) Gene polymorphisms in vegf and vegf receptor 2 as markers for cancer therapy
WO2008132763A3 (en) Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
WO2012018613A3 (en) Genetic make-up modifies cancer outcome
WO2008112898A3 (en) Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
EP3219813A3 (en) Methods for treating, diagnosing, and monitoring lupus
EP2155705A4 (en) COMPOSITIONS FOR REGULATING OR MODULATING QUORUM DETECTION IN BACTERIA, METHODS OF USING THE SAME, AND METHODS OF REGULATING AND MODULATING QUORUM DETECTION IN BACTERIUM
WO2007030611A3 (en) A calculated index of genomic expression of estrogen receptor (er) and er related genes
CA2686874C (en) Polymorphism in the apo(a) gene predict responsiveness to acetylsalicylic acid treatment
MX2007011493A (es) Modalidades antiinflamatorias.
WO2008088855A3 (en) Gene polymorphisms as predictors of tumor progression and their use in cancer therapy
TW200624253A (en) Polymer sheets comprising higher order phosphate esters
MX2010002993A (es) Uso de clec1b para la determinacion de riesgo cardiovascular y trombotico.
MX2011007989A (es) Marcadores para predecir y verificar la respuesta a terapia de inhibidor de aurora cinasa b.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130426